Abstracts/Lung Cancer 13 (1995) 81-104

The use of high resolution OIgorithms and thick sections lor CT. staging of bronchial carcinomas lend H-H, Schreiber A. Aadrologrsches Zenrrum. Zenfralkrnnkenhous Rrewn-Osr. Zunche, Shasse do, D-28325 Bwnen. Rofo Fortschr Geb Ron,eenstr Netter, Bddeebendcn Verfahren 1995: 162: 134-9

The purpose was ,o&emd”e whether 8 m m slice seaions wilh high rcs&~wm algorithms weld prove superior ,” standard melhcds for the CT s,agmg of bronch,al carcmomas The raw data from CT exammations in 50 pa,ien,s using standard methods and the high resolu,ion method was calculated. dccumenled and compared Within the lung parenchyma. small foe, or me-. peritumcarota ~Niltrates, bronchml narrowing, bronchml “ullines, vessels and awas of poor acratmn were signiticanlly clearer Pleural thzkening and subpleural far s,npeswerealsobe,,crseen. Abnomwli,,es inche mediastmum were equally well shown H,gb resolution algorilhms wilh 8 m m slice secdons are recommended for routine s,ag,ng of bronchial carcinomas, panicularly ,f the calculations can be done quickly, as is possible on modem apparalus. withou, increasing ,he durauon of Ihe exammation

Diagnostic and prognostic value of the new turnour marker

CYFRA 21-I in patients with squamous cell lung cancer Niiinski I, Fur”& hi, Chycz&a E, Chyczwski i, Laudanski I. Lkmmtent Thoraw Sunew. Medical School. 24~ M. slrlodow-Cum iti, IS-276 Btolysrock E;r kespir J 1995.8:291-4.

We wanted to investigate the diagnostic and pmgwstic significance of serum CYFRA 21-1, especmlly in predicting fhe risk of recurrence in patients with operable quamws all hng cancer Serum levels of CYFRA 21-l were mraured using an immunoradiomclric assay (CIS bio) in 16 patients with squamous all lung cancer (64 operable and I2 w,h unreseaable ,um”urs). 22 rvlth other non-smallall type (12 wilh ademrmcinmns and IO with largeall trpc) and 45 wilh nonmalig,mn, lung diseases. Elevated prmpem& CYFRA 21-l levels wem ide”tlfied in 63% of oalients with sauam”us cell type (SqCC), 33% w,th adenocarcmoma. and IO%‘wi,h large-ceil &&ma type. The Qagtonic spaticuy ofthe assay war 96%. Positive CYFRA 2 I-I levels were observed in 33%ofstage 1,52%ofnage II, 76%ofsrage llla and 83% of Uage Illb patients w,h SqCC type. S,m,s,ically sigmticant differences were obtamed t&wee” nages I and II and belween II and Illa, hut no, between stages llla and lllb Recurrence-free s~l~,~al pmbatnlity for patients w,,h elevated serum CYFRA 2 t-l levels before sumew was 63% (24138) vems 92% (241/6) for palien& wlh normal s.&m~CYFltA 2 1-l levels However. the ,htfem& was “M slatis,,cally mgndicant when adjusted for the TNM stage (primary lumour, regional lymph wd.e involvement, acurrence of dwan, memslas,s). In 9 of the IO paents with increased trend for CYFRA 21-l durmg follow-up, elevated serum CYFRA 21-l kvels preceded (7) or comadad (2) with the chnical deteaion of ,umcmr reaurence. providing a predvztive value ofan i”crcascdmmdof9c56. In,h:mull~nna,eanalysis.,heazsocjation of ,he mcrease of CyRlA 21-I level w”h a higher nsk of recurrence was s~al~st~callv SumiRcant Our resuhs mdicale ,hal CYFRA 2 I- I may be a useful ma;ke;in SqCC Serial determmation of 0’FP.A 21-l was cons,s,en, w,h ,he treatment results and the serum CYFRA 2 l-l levels wereshow”,“refl~,,he~seasepmcessdunngfollow-up. Risingserum CYF!U 21-I levels ,n padems af,er ,um”ur resectmn were an early ,nd,ca,or oi,umour recurrenw

Somatostrtin receptor imaging of small cell lung cancer (SCLC) by means of “‘In-DTPA octreotidc scintigraphy Bombardieri E, Crippa F. Cataldo I. Chili A, Seregni E, Sores, E et al Deparhcnt of Nuclear Medrcine. lstrluro Nazronole Tumorr. Mo Venezum 1. 20133 Milan. Eur J Cancer Par, A Gen Top 1995;3 I: 184~ 8.

Samatmtatin receptors have been &-scribed on the membrane of neoplastic cells derived from the AF’UD system and their expression has also heat demonstrated on small all lung cancer (SCLC) in vitro and in viva. 21 patients wilh SCLC were studied using “LIn-cc&o,,de (“‘In-0ClJ scinti8mphx ScmtiaraDhic examinations were perfOrmed foUo~nginuavcnous(i.v.) inpaiW”f It I MBq lQK,CT&hwhole- body scintigmphy and planar aintigraphy of the thorax as well as the SPET technique. No shan-,ema side effects were described following “‘tn-0C’f adminislra~ion. We studied the “UOCT budistnbution in 3 DatienUwithscrtal scinugra~hicsat I. 5 and24 h. WeusedtheS has s&lard scanning time forlbeiollowing I8 patienls. The scinligraphic results were compared with IhoPe of other mnventional &agnostic pmcedwes “‘In-ocTde~~86%(48/56)ofthclesi~alreadylolown a, the ctme of scinrigraphy. It was positive in all 20 SCLC patmnts and

negative in one lung adenccarcmoma “‘h&CT showed hrgh sensilivrty for medms,,nal “etastases (94%) and good sensitivity for bone melilstases (75%) and abdominal lymph node metas,ases (71%). “‘In- OCT did no, detest two liver metasfases. “‘In-0CT detected five unknown lemons which were confirmed by o,her diagnos,,c examtnat~ons. “‘In-OCT was also effecdve in cancer pauents wifh low IewlsoiNSE. Oursludyslwws tha, “‘In-0CTsci”tigraphy isa reliable. “on-mvaswe technique to delen primary SLCL and 1,s locoregional or distant mefas&scs. The clitical u,ili,y oirscep,or sc81us chara&risation dxmned wilh “~In-OCT ximigraphy should be evalualed by means of an appmpriale pmspective sludy.

Epidermal gmwtb factor receptor (EGFr) expression in non- small cell lung carcinomas correlates with metrstatic involvement of hilar and mediastinal lymph nodes in the squamous subtype Fonmmni G, Vignati S, Bigmi D, Mussi A, Lucch, H, An8elem CA e, al. hsl~Nle o/Porhology Y,S, Rome 57, PISO. Em J Can& Pa, A Gen Top 1995;31:178-83.

Epidermat growlh factor rccepmr (EGFr) levels were evaluated I” paraffin-embedded turnour spwmens oi nonsmall cell lung cancer (NSCLC) firm, 176 patienls who underwent surgical rezectmn The EGFr expression was evaluated by immunocyxchemical assay usmg a monoclorial antibody which recognizes the external doma,” of ,he reccplor. EGFr immmmreactivity was s~gnificanlly higher in squamous than in non-squamous cell carcinomas (P = 0 0009) Hilar and/or mediastinal nodal involvement was found I” 29 of 10s (27 4%) squamcm~ WICHS. and in this group of padents. ,he mea” of EGFr c&live c?lts was sieruticandv hipherlhan llut oi~at~enls without nodal &“lvemenl (P = 0.01). No signir-,cant correla&s were found berwcen the expression of EGFr and other cliniwpalhologxal or bmlogacal parameters such as T-status, gradmg, proliferatwe activity EGFR ,s su~ested to represent a useful ,ndicator of n&l me,as,as~s ,n NSCLC

Significawe of plasma ANP assay in patients with lung cancer Gao J-F. Wu H-Y. Luo H-X. Depwfmmr o/Resprrarory Medrcmr, Wuhan GeneralHosprtol. PL4, Wuhan ChinJCl,nOrrol 1995:22: 1C6- 9

Plasma ANP (Atnal Nauwe,ic Pepdde Production) wasde,emdned ,n 75 palients with primary lune cancer. 32 wauenfs vn,h knism lune d1seaxand32 no~li~~idua~wi,b,echni$ueoimd~o,mmu~sa~ Level of AN? I” pa,,en,s w,h lung cancer was remarkably tngher than m ,hc co”lr016 (P < 0 01) In palients wlh small cell lung cancer I, was much tugher than lhose with squamous cell caranoma and adenaadmma(P<O.Ol) Nodrff’nencz inhween,hedlBcren, nags of lung cancer (P > 0 05) The pwtwe ralc of ANP m pabents w”h lung cancer was 46 47% The lcvcl of ANT’ in pa,,cn,s w,,h lung cancer decrcascd markedly p~sl~peratrvcly (P < 0 01, I, 1s concluded ,ha, ,hc delermlnatmn of plasma ANP IS helpful 3” dlagnosls. haslologic class~hcalmn and monitorwig ,he response lo thcrapj m paenls wrth lung cancer

Symptoms at presentation for treatment in patients with lung cancer: Implications for the evahmtion of palliative treatment Hopwood F’, Stephens RI. Bleehen NM. Bolger II, Clark PI, Girling DJ et ;I. CRC P;ychologicsl Medrcrnr Gmup. Chrrstre Hosprtal. Mmchester A420 4B.K Br J Cancer 1995;71:633-6.

The ten “vast tieqwntly reported pretrea,ment symptoms on ,he Rcacrdam Symptom Cbxklist. which was completed by m”re than 650 patientsentering tH0 hfRC Lung Canal M&ingParty multicenue random&d trials, included general symptams (tiredness, lack of appetite) and psychological distress (wony. anxiety) in add,t,on Lo disease-related ches, symptoms (cough. shori”ess ofbreath). Although the number and severity of symptoms increased with worsemng pcrfomta”cx stahts, tie cimnmnest sympt~“~s wre found 1” be vir,ually the same for patients with small-cell lung cancer (SCLC) and “on- small.cell lung cancer (NSCLC), and fordiffere”, grades of performance status Women with NSCLC reported m”re psychological sympems than males. but this difference was much less evident ,n patients wth SCLC. Thus. in order ,” assess hdly the bend, of palliatwe weatmen(z in patlenu with lung cancer, accou”, mun be taken of all symp,mns a, present&oh inadd,tian u) thctrrulitionally recognised chest symptoms.